Zydus Gets USFDA Nod for Generic Ibrutinib

Jul 24, 2025 13:35

Zydus Lifesciences receives tentative USFDA approval for its generic Ibrutinib tablets, used to treat various blood cancers. Annual US sales of Ibrutinib are USD 2.15 billion.

New Delhi, Jul 24 (PTI) Zydus Lifesciences Ltd on Thursday said it has received tentative approval from the US health regulatory agency for its generic version of cancer treatment drug Ibrutinib tablets.

The tentative approval granted by the US Food and Drug Administration (USFDA) is for Ibrutinib tablets of strengths 140 mg, 280 mg, and 420 mg, Zydus Lifesciences said in a statement.

The Ibrutinib tablets will be produced at Zydus Lifesciences Ltd SEZ, Ahmedabad, it added.

The company said Ibrutinib is indicated for the treatment of adult patients with different types of blood cancers, Chronic lymphocytic leukaemia (CLL)/Small lymphocytic lymphoma (SLL), and Waldenstrom's macroglobulinemia (WM).

Citing IQVIA MAT May 2025, Zydus said Ibrutinib tablets had annual sales of USD 2148.9 million in the US.

Source: PTI

MORE NEWS

Unilever: India Growth & GST Impact

Unilever sees huge opportunities in India due to high GDP growth and GST cuts. HUL...

Trai Recommends 6 GHz, E, V Band Allocation

Trai suggests administrative allocation of 6 GHz, E, and V bands for telecom backhaul....

TotalEnergies Sells Stake in Adani Green Energy

TotalEnergies sells 1.74% stake in Adani Green Energy for Rs 2,778 cr. Stake reduced to...

TCS Acquires Coastal Cloud for $700 Million

TCS acquires Coastal Cloud for USD 700 million, strengthening its Salesforce and AI...

JSW Paints Acquires AkzoNobel India Stake

JSW Paints completes acquisition of majority stake in AkzoNobel India, becoming the...

Park Medi World IPO Subscribed 52% on Day 1

Park Medi World''s IPO received 52% subscription on day 1. The Rs 920-crore IPO closes...

Dasnac Invests Rs 2,000 Cr in Noida Luxury Housing

Dasnac to invest Rs 2,000 crore in a luxury housing project, Dasnac Westminster, in...

Nephrocare IPO Subscribed 12% on Day 1

Nephrocare Health Services IPO received 12% subscription on day 1. IPO details, price...

Wakefit IPO Subscribed Over 2 Times

Wakefit''s Rs 1,289-cr IPO was subscribed over 2 times on the final day. Details on...

IAN Group to Deploy USD 100M Alpha Fund by 2027

IAN Group to deploy its USD 100 million IAN Alpha Fund in early-stage startups by 2027....

Zydus Gets USFDA Nod for Generic Ibrutinib

You May Like To Read

MORE NEWS